Core Viewpoint - Apollomics Inc. reported its financial results for the first half of 2025, highlighting a significant reduction in net loss compared to the same period in 2024, alongside ongoing development of its oncology drug candidates [1][7]. Financial Performance - Cash, cash equivalents, bank deposits, and money market funds as of June 30, 2025, were $2.1 million, down from $9.8 million as of December 31, 2024 [7]. - Research and development (R&D) expenses for the first half of 2025 were $4.6 million, a decrease from $16.9 million in the first half of 2024 [7]. - General and administrative (G&A) expenses were $14.5 million for the first half of 2025, compared to $10.2 million in the same period of 2024 [7]. - The net loss for the first half of 2025 was $(12.5) million, or $(11.37) per basic and diluted share, compared to a net loss of $(35.2) million, or $(37.53) per basic and diluted share, for the first half of 2024 [7][14]. Asset and Liability Overview - Total assets as of June 30, 2025, were $11.1 million, down from $13.1 million as of December 31, 2024 [10]. - Current liabilities increased to $10.5 million as of June 30, 2025, from $7.4 million as of December 31, 2024 [10]. - The company reported net liabilities of $(4.4) million as of June 30, 2025, compared to net assets of $4.9 million at the end of 2024 [11]. Company Overview - Apollomics Inc. is focused on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial [3].
Apollomics Reports First Half 2025 Financial Results